The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a dihydroorotate dehydrogenase (DHODH) inhibitor, wherein the cancer has an altered glutathione peroxidase 4 (GPX4) expression as compared to a control sample. The present disclosure also provides methods of treating a subject with a dihydroorotate dehydrogenase (DHODH) inhibitor where the subject's GPX4 expression is low as compared to a control sample or with a DHODH inhibitor and a ferroptosis inducer where the subject's GPX4 expression is high as compared to a control sample.

The invention relates to biotechnology and provides novel recombinant DNA molecules and engineered proteins for conferring tolerance to protoporphyrinogen oxidase-inhibitor herbicides. The invention also provides herbicide tolerant transgenic plants, seeds, cells, and plant parts containing the recombinant DNA molecules, as well as methods of using the same.

The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.

A transgenic corn event, Zm_CSM63715, is provided. Transgenic plant cells, plant parts, plants, seeds, progeny plants, and agricultural and commodity products containing event Zm_CSM63715 are also provided. Recombinant DNA molecules unique to the event Zm_CSM63715, and methods of using and detecting Zm_CSM63715 are also provided. Corn plants containing the event Zm_CSM63715 exhibit tolerance to PPO inhibitors.

Described herein are biological devices and extracts useful for detecting Alzheimer's disease and/or concussions. The biological devices include microbial cells transformed with a DNA construct containing genes for producing -amyloid precursor protein, microtubule associated protein tau, adipose triglyceride lipase, acyl-CoA dehydrogenase, and O-linked N-acetylglucosamine transferase. In some instances, the biological devices also include a gene for enhanced green fluorescent protein. Methods for using the devices to diagnose or detect Alzheimer's disease and/or concussions are also provided herein.

The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type or a mutated protoporphyrinogen oxidase (PPO) which is resistant or tolerant to a benzoxazinone-derivative herbicide by applying to said site an effective amount of said herbicide. The invention further refers to plants comprising wild-type or mutated PPO enzymes, and methods of obtaining such plants.

This application discloses methods for treating a cancer that has metastasized to the brain in a subject using a therapeutically effective amount of HydroxyUreaMethyl Acylfulvene. In addition, pharmaceutical compositions having HydroxyUreaMethyl Acylfulvene and a pharmaceutically acceptably carrier, diluent, excipient, or a combination thereof are disclosed.

Devices and methods for sensing analytes in a solution sample are provided. The device includes a substrate, a conversion component configured to convert the analyte in the sample solution into a metabolite, and an aptamer sensor configured to measure a presence of the metabolite, the aptamer sensor located on the substrate.

The invention relates to 5-fluoro-2-deoxyuridine-5-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, in particular by intravenous infusion for a continuous period of up to 10 hours. The invention also relates to methods of treating cancer by administration of NUC-3373 to particular sub-groups of cancer patient. The invention further relates to methods for selecting a patient for treatment with NUC-3373.

The present invention is directed towards methods for treating non-alcoholic fatty liver disease (NAFLD) in a patient and determining prognosis of NAFLD in a patient.